The company's intravenous engineered bacteriophage drug uses antibacterial small acid-soluble spore proteins to prevent the release of toxins, inactivating the DNA of pneumonia bacteria to stop it from reproducing and spreading. Phico's patented platform utilizes an antibacterial protein, SASP, to cause rapid destruction of target bacteria, providing a new generation of antibiotics to overcome antimicrobial resistance.